few large-scale studies revealed the clear correlation between age, tumor nodes metastases (TNM) staging and morbidity in this rare population. Method: The age of ALK-positive lung cancer at initial diagnosis were compared between various TNM stages. Clinical characteristics, morbidity and prognosis were analyzed stratified by different age groups. Results: Of 411 patients, the younger group showed more frequent T3/4 stage (P ¼ 0.014), more frequent lymph nodes metastasis (P ¼ 0.011) and more frequent distant metastasis (P ¼ 0.015). Across the entire patient cohort, the median age was 51 years, which decreased steadily with clinical stages (stage I/II vs. III vs. IV, 55 vs. 52 vs. 49 years). There was significant inverse correlation between age and clinical stages (P < 0.001). These laws also existed at various T, N, M categories. What was more, morbidity of ALK rearrangement manifested a steady downward trend with older age groups (40 vs. 40-49 vs. 50-59 vs. 60 years: 18.8% vs. 11.6% vs. 5.0% vs. 2.2%). Surprisingly, ALK-positive patients with stage IIIb-IV disease had much higher incidence than the patients with stage I-IIIa disease (6.1% vs. 3.4%, P < 0.001). Finally, the ALK-positive patients aged younger showed poorer outcomes compared with the older group. Conclusion: TNM staging exhibited a significant inverse correlation with age in ALK-positive lung cancer. More unique therapeutic and research strategies should be required in these patients of young age. Keywords: ALK-positive lung cancer, TNM staging, inverse correlation, age 
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Here, we explored the genetic characteristics in different HER2 mutations and co-mutations and their impact on responses to afatinib in NSCLC patients. Method: Eighty-six HER2-mutant lung cancer patients who were referred to OrigiMed (Shanghai, China) for NGS-based genomic testing were identified (OrigiMed cohort). The frequency and distribution of genomic alterations were analyzed with a 37 or 450 gene panel with a mean coverage depth of >800X. Another 32 HER2-mutant adenocarcinoma patients who treated with afatinib were identified (Afatinib cohort). Clinical outcomes on afatinib were retrospectively evaluated according to types of HER2 mutations. The most common mutation A775_G776insYVMA were classified into Group 1; Group 2 contained other exon 20 insertions; Group 3 contained missense mutations. Results: The frequency of HER2 mutation was 4.23% (86/2035), which was higher than those observed in TCGA (15/ 546, 2.75%) and MSK-IMPACT (45/1275, 3.53%). Thirty-one different HER2 mutations were detected in OrigiMed cohort. The most frequent HER2 mutations in two cohort were A775_G776insYVMA (35/86; 14/32), G778_P780dup (6/86; 5/32), G776delinsVC (4/86; 5/32) and S310F/Y (7/86; 1/32). A775_G776insYVMA and G776delinsVC/G778_P780dup respectively correlated with the worst and the best clinical outcomes on afatinib in overall response rate (P¼0.018), disease control rate (P¼0.001) and progression-free survival (PFS) (Figure 1) 
